These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31139907)

  • 1. From indecision to precision: advances in imaging in metastatic prostate cancer.
    Bolton D; Frydenberg M
    World J Urol; 2019 Jul; 37(7):1237. PubMed ID: 31139907
    [No Abstract]   [Full Text] [Related]  

  • 2. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
    Hussain M; Lin D; Saad F; Vapiwala N; Chapin BF; Sandler H; Evans CP; Carducci MA; Sachdev S
    J Clin Oncol; 2021 Jan; 39(1):13-16. PubMed ID: 33048621
    [No Abstract]   [Full Text] [Related]  

  • 3. Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
    Mertan F; Turkbey B
    Pharmacol Res; 2016 Dec; 114():163-165. PubMed ID: 27777131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Widespread metastases in small cell carcinoma of the prostate on FDG PET/CT.
    Yilmaz M; Celen Z; Sevinc A; Karakok M
    Clin Nucl Med; 2009 Sep; 34(9):598-600. PubMed ID: 19692822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with
    Sobol I; Zaid HB; Haloi R; Mynderse LA; Froemming AT; Lowe VJ; Davis BJ; Kwon ED; Karnes RJ
    J Urol; 2017 Jan; 197(1):129-134. PubMed ID: 27449262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology.
    Jadvar H
    J Nucl Med; 2018 Sep; 59(9):1338-1339. PubMed ID: 30030344
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.
    Robertson NL; Sala E; Benz M; Landa J; Scardino P; Scher HI; Hricak H; Vargas HA
    J Urol; 2017 Jul; 198(1):65-70. PubMed ID: 28216327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.
    Albisinni S; Aoun F; Marcelis Q; Jungels C; Al-Hajj Obeid W; Zanaty M; Tubaro A; Roumeguere T; De Nunzio C
    Minerva Urol Nefrol; 2018 Aug; 70(4):347-360. PubMed ID: 29388415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging the High-risk Prostate Cancer Patient: Current and Future Approaches to Staging.
    Bjurlin MA; Turkbey B; Rosenkrantz AB; Gaur S; Choyke PL; Taneja SS
    Urology; 2018 Jun; 116():3-12. PubMed ID: 29545055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular research in urology 2014: update on PET/MR imaging of the prostate.
    Wetter A
    Int J Mol Sci; 2014 Jul; 15(8):13401-5. PubMed ID: 25089874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic utility of positronic emission tomography in recurrences of prostate cancer].
    Petrovskiy NV; Glybochko PV; Dolgushin MB; Krupinov GE; Shariya MA; Meshcheryakova NA
    Urologiia; 2019 Dec; (5):126-131. PubMed ID: 31808647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer.
    Eschmann SM; Pfannenberg AC; Rieger A; Aschoff P; Müller M; Paulsen F; Anastasiadis A; Claussen CD; Bares R; Schlemmer HP
    Nuklearmedizin; 2007; 46(5):161-8; quiz N47-8. PubMed ID: 17938748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of recurrent and metastatic prostate cancer with novel tracers.
    Mertan FV; Lindenberg L; Choyke PL; Turkbey B
    Future Oncol; 2016 Nov; 12(21):2463-2477. PubMed ID: 27527923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
    Ahuja A; Taneja S; Thorat K; Jena A
    Clin Nucl Med; 2017 Dec; 42(12):e509-e510. PubMed ID: 29036003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pro and contra: 11C choline PET in diagnosis of prostate cancer].
    Kotzerke J; Zöphel K; Salomon G; Graefen M; Heidenreich A
    Aktuelle Urol; 2007 May; 38(3):189-94. PubMed ID: 17566231
    [No Abstract]   [Full Text] [Related]  

  • 16. Dynamic PET/CT with 11C-acetate in prostate cancer.
    Schiepers C; Huang SC; Dahlbom M
    J Nucl Med; 2013 Feb; 54(2):326. PubMed ID: 23264690
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in Imaging in Prostate and Bladder Cancer.
    Srivastava A; Douglass LM; Chernyak V; Watts KL
    Curr Urol Rep; 2017 Sep; 18(9):69. PubMed ID: 28718164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancement of MR and PET/MR in Prostate Cancer.
    Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
    Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of prostate cancer.
    Akin O; Hricak H
    Radiol Clin North Am; 2007 Jan; 45(1):207-22. PubMed ID: 17157630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Al-Bayati M; Grueneisen J; Lütje S; Sawicki LM; Suntharalingam S; Tschirdewahn S; Forsting M; Rübben H; Herrmann K; Umutlu L; Wetter A
    Urol Int; 2018; 100(2):164-171. PubMed ID: 29393268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.